FPT Corporation: Targeting the Top 50 Global Digital Transformation Service Providers by 2030
8.4.2022 12:47:00 EEST | Business Wire | Press release
In the Annual General Meeting 2022 (AGM 2022), FPT Corporation (FPT) has announced its goal to be among the Top 50 global end-to-end digital transformation service providers by 2030 and plans to continue working toward the long-term goal of becoming a standard-bearing digital enterprise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220408005158/en/
FPT Chairman Truong Gia Binh at the Annual General Meeting 2022 (Photo: Business Wire)
Last year marked FPT’s effort to “rebirth” as the number of projects worth over 5 million USD increased by 111%. The firm’s global revenue in 2021 reached 1.6 billion USD, which grew nearly 20% year on. Foreign markets also recorded positive growth, including the Americas (+52%) and APAC (+27%).
FPT has pledged to become a strategic partner for businesses worldwide. In the 2022 - 2024 period, FPT shall continue to pursue this orientation, with the core mission of “Promoting rapid growth, developing new technology products, and providing digital transformation services on a large scale”, as mentioned by FPT Chairman Truong Gia Binh in FPT’s 2021 Annual Report.
To achieve this mission, Vietnam’s largest IT services provider plans to continue projecting on a balanced basis in three core pillars: Business – Governance – Technology. As Dr. Binh emphasized during the meeting, it is the firm’s strategy to provide comprehensive solutions to meet global businesses and each individual’s most basic demands.
With customers varying from large private enterprises, SMEs to individuals, FPT thrives on accommodating each group with unique services, combining different technologies to enhance business management, administration, and most importantly, customer services at every touchpoint. This highlights the firm’s growth strategy based on data-driven operations, a customer-centric motto, and breakthrough technology solutions.
According to FPT CEO Nguyen Van Khoa, technology-wise, the firm will leverage on-trend technologies to provide world-class digital transformation solutions and realize breakthrough opportunities for its shareholders.
As Vietnam’s technology pioneer, FPT plans to invest heavily in core technologies such as AI, Cloud, Big Data, Blockchain, and Hyper Automation. The Made-by-FPT ecosystem is also targeted as FPT's key growth driver in the long term, with a revenue growth rate of 42.8% in 2021.
FPT sets its message for 2022 to be: “Determined to fight” and plans to innovate in business and sales activities, expand its customer base in all sizes and fields globally. Promoting a long-term sustainable growth strategy, the firm targets a 19% growth in revenue and 20.2% in profit before tax for the following year.
About FPT Corporation
FPT Corporation is a globally leading technology and IT services provider headquartered in Vietnam, with nearly US$1.6 billion in revenue and 37,000 employees. As a pioneer in digital transformation, FPT delivers world-class services in Smart factories, Digital platforms, RPA, AI, IoT, Enterprise Mobility, Cloud, AR/VR, Business Applications, Application Services, BPO, and so on. The company has served over 1000+ customers worldwide, 85 of which are Fortune Global 500 companies in Aerospace & Aviation, Automotive, Banking and Finance, Logistics & Transportation, Utilities, and more. For more information, please visit www.fpt-software.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005158/en/
Contact information
Media
Mai Duong (Ms.)
FPT Software
PR Manager
Email: MCP.PR@fsoft.com.vn
Website: https://www.fpt-software.com/newsroom/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom